Coming soon

Ask REGTEKA AI is on its way.

Ask regulatory questions across REGTEKA intelligence.

Hear when it launches: the Regulatory Briefing

HomeCompaniesAstraZeneca

Company

AstraZeneca

Cambridge, UK-headquartered biopharmaceutical company; markets Ultomiris through Alexion, its rare-disease unit, where ravulizumab is already approved for PNH, atypical HUS, generalized myasthenia gravis and NMOSD.

astrazeneca.com

3 stories

Regulatory News has published 3 stories about AstraZeneca between 20 September 2026 and 25 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 25 October 2026.

This page is generated from Regulatory News’ editorial coverage of AstraZeneca. It is not an advertisement.

Products in our coverage

Our coverage

3 stories, newest first.

A confident executive in a bright office, a generic stand-in for AstraZeneca/Alexion leadership For Physicians Ultomiris Cleared for IgAN; Kidney Benefit Still Unproven Oct 25, 202612 min read Read the story A confident executive holding a clipboard in a bright, minimal office, a generic stand-in for AstraZeneca leadership Drugs & Biologics FDA Clears First C5 Inhibitor for IgA Kidney Disease Oct 25, 20266 min read Read the story Two officials in dark suits sign documents at a conference table with a European Union flag between them Drugs & Biologics CHMP Backs AstraZeneca's Klygefa for Rare Disorder Sep 20, 20265 min read Read the story

All companies